EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology

Bart van Lieshout iD, Aanisah Hanuun iD, J G Coen van Hasselt iD, Rob C van Wijk iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Bart van Lieshout und 3 weiteren Autor:innen. Beteiligte Einrichtung: Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Mycobacterium Infections, Nontuberculous, Mycobacterium marinum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish ( Danio rerio ) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model to study early anti‐tuberculosis drug pharmacology and bridge the gap between in vitro drug screens and (confirmatory) rodent experiments. This study aimed to translate the bedaquiline exposure–response relationship from zebrafish to humans to predict two phase 2a trial results in order to strengthen the use of zebrafish as a New Approach Methodology for translational anti‐tuberculosis pharmacology. An established exposure–response relationship for bedaquiline in zebrafish against Mycobacterium marinum as a tuberculosis disease model was combined with a clinical population pharmacokinetic model to predict bacterial burden profiles from two published phase 2a clinical trials (25 to 400 mg daily). This translation incorporated the minimum inhibitory concentration ratio between Mycobacterium marinum and Mycobacterium tuberculosis to scale the zebrafish bedaquiline EC 50 to humans. Clinical simulations based on the scaled zebrafish exposure–response relationship demonstrated that accounting for in vitro drug sensitivity resulted in close alignment with observed bacterial burden across all doses and timepoints, with a mean absolute percentage error of 10.37% and a root mean squared error of 0.74 log 10 colony‐forming units per milliliter of sputum. These findings demonstrate that early‐phase clinical results for bedaquiline in tuberculosis can be successfully predicted from pharmacokinetics–pharmacodynamics in the zebrafish tuberculosis disease model. These results help advance the zebrafish as a resource‐efficient and sustainable New Approach Methodology for tuberculosis drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsDiarylquinolinesMycobacterium Infections, NontuberculousMycobacterium marinumTranslational Research, BiomedicalTuberculosisAnimalsHumansClinical Trials, Phase II as TopicDisease Models, AnimalDose-Response Relationship, DrugMicrobial Sensitivity TestsZebrafish

Substanzen

Antitubercular AgentsbedaquilineDiarylquinolines

Autor:innen und Institutionen

  • Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

ORCID-Profile: Bart van Lieshout, Aanisah Hanuun, J G Coen van Hasselt, Rob C van Wijk

Zitieren

APA

van Lieshout, B., Hanuun, A., van Hasselt, J. G. C., & van Wijk, R. C. (2026). Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70430

Vancouver

van Lieshout B, Hanuun A, van Hasselt JGC, van Wijk RC. Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70430

BibTeX
@article{vanLieshout2026,
  author = {van Lieshout, Bart and Hanuun, Aanisah and van Hasselt, J G Coen and van Wijk, Rob C},
  title = {Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70430}
}
Kostenlos starten →